List of Excipients in Branded Drug MONTELUKAST SODIUM ORAL

Generic Drugs Containing MONTELUKAST SODIUM ORAL

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	montelukast sodium oral	13668-531	HYDROXYPROPYL CELLULOSE
Torrent Pharmaceuticals Limited	montelukast sodium oral	13668-531	MAGNESIUM STEARATE
Torrent Pharmaceuticals Limited	montelukast sodium oral	13668-531	MANNITOL
Torrent Pharmaceuticals Limited	montelukast sodium oral	13668-531	SODIUM PHOSPHATE, TRIBASIC

What are the Most Frequently-Used Excipients in MONTELUKAST SODIUM ORAL?

# Of NDCs	Excipient
1	HYDROXYPROPYL CELLULOSE
1	MAGNESIUM STEARATE
1	MANNITOL
1	SODIUM PHOSPHATE, TRIBASIC

Montelukast Sodium Oral Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Montelukast sodium oral products are mature generic medicines with limited active-ingredient patent barriers. Commercial differentiation depends on excipient selection, pediatric usability, taste masking, dosage-form convenience, allergen control, supply reliability, and regulatory execution. The strongest opportunities are alcohol- and sugar-free pediatric products, orally disintegrating or fast-dispersing tablets, low-volume granules, and formulations that remove aspartame, lactose, or selected colorants.

What is the current market status of montelukast sodium oral products?

Montelukast is a leukotriene receptor antagonist marketed originally by Merck as Singulair. FDA-approved oral products include 10 mg film-coated tablets for adults and adolescents, 5 mg and 4 mg chewable tablets for pediatric patients, and 4 mg oral granules for younger children.[1]

Montelukast sodium is used for:

• Asthma maintenance therapy
• Exercise-induced bronchoconstriction
• Seasonal allergic rhinitis
• Perennial allergic rhinitis

The product is administered once daily. The oral market is genericized, and commercial competition is driven primarily by price, supply continuity, channel access, formulation usability, and product differentiation rather than by exclusivity around montelukast itself.

The FDA requires a boxed warning for serious neuropsychiatric events, including suicidal thoughts or behavior. The warning affects prescribing and labeling strategy but does not create an excipient-specific barrier.[1]

Core oral presentations

Dosage form	Typical strength	Primary patient group	Commercial role
Film-coated tablet	10 mg	Adults and adolescents	High-volume generic baseline
Chewable tablet	4 mg, 5 mg	Children	Taste, texture, and excipient-sensitive segment
Oral granules	4 mg	Young children	Administration flexibility and pediatric differentiation

The pediatric segment is more dependent on excipient performance than the 10 mg tablet segment. Taste, mouthfeel, swallowing, dosing flexibility, and caregiver handling directly affect acceptance and adherence.

What excipients are used in montelukast sodium oral products?

Approved reference products use different excipient systems according to dosage form. Singulair tablets contain conventional tablet excipients, while chewable tablets and granules rely more heavily on sweeteners, flavor systems, and particle engineering.[1]

Representative excipient functions

Excipient category	Typical examples	Function in montelukast products
Diluent	Mannitol, microcrystalline cellulose, lactose	Bulk, compressibility, dose uniformity
Binder	Hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Croscarmellose sodium	Tablet breakup and dispersion
Lubricant	Magnesium stearate	Ejection and manufacturing control
Sweetener	Aspartame, sucralose, mannitol	Taste masking and palatability
Flavor	Cherry or fruit flavor	Suppression of active-related bitterness
Coating polymer	Hypromellose	Film protection, appearance, swallowability
Colorant	Iron oxides, titanium dioxide	Product identification and appearance
Glidant or flow aid	Colloidal silicon dioxide	Powder flow and content uniformity

The formulation target is not simply rapid disintegration. Montelukast has a strong taste profile, and pediatric formulations must control bitterness during the time the product remains in the mouth. A highly porous tablet that disintegrates rapidly can increase exposure of the active ingredient unless taste masking is engineered at the particle or matrix level.

What excipient strategy is best for montelukast sodium chewable tablets?

A commercial chewable formulation should prioritize taste masking, low friability, rapid but controlled disintegration, and acceptable mouthfeel. The most practical platform is a mannitol-based direct-compression or granulated tablet with an intensive flavor and sweetener system.

Recommended chewable-tablet design

A robust design typically includes:

• Mannitol as the principal diluent for cooling mouthfeel and low hygroscopicity
• Microcrystalline cellulose for compactibility
• Croscarmellose sodium for rapid breakup
• A low-use-level binder such as hydroxypropyl cellulose
• Magnesium stearate at a controlled level to limit dissolution impact
• A fruit flavor selected through pediatric sensory testing
• A high-intensity sweetener system that does not rely solely on aspartame
• Optional polymeric coating or coated active particles for bitterness reduction

The main formulation risk is an imbalance between hardness and sensory performance. Higher compression force can reduce friability but delay tablet breakup. Higher lubricant levels can impair wetting and dissolution. Excessive flavor can create a harsh aftertaste or regulatory variability between batches.

Aspartame-free opportunity

Reference chewable products may use aspartame, which requires phenylalanine labeling for patients with phenylketonuria.[1] An aspartame-free product can create a clear commercial distinction, particularly in pediatric and institutional channels.

Potential replacement systems include:

• Sucralose with fruit flavor
• Acesulfame potassium combinations
• Steviol glycosides blended with masking agents
• Polyol systems using mannitol or xylitol
• Encapsulated sweeteners for delayed release in the oral cavity

The formulation should avoid excessive polyol loading because gastrointestinal tolerability, tablet size, hygroscopicity, and compression behavior can become limiting factors.

What excipient strategy is best for montelukast sodium oral granules?

Oral granules are the most technically attractive pediatric format because they can be administered directly or mixed with selected soft foods. The FDA label for montelukast granules specifies administration requirements, including use immediately after opening and restrictions on mixing with liquids.[1]

A differentiated granule product can compete through:

• Improved flow and sachet emptying
• Lower dust generation
• Better taste masking
• More uniform dispersion in soft food
• Reduced moisture sensitivity
• Smaller sachet fill volume
• Easier caregiver handling

Granule platform options

Taste-masked multiparticulates

Layering or coating montelukast particles with a polymeric barrier can reduce immediate bitterness. Suitable technologies may include fluid-bed coating, spray congealing, hot-melt coating, or lipid-based encapsulation.

The main development variables are:

• Coating weight gain
• Release in the gastrointestinal tract
• Particle size distribution
• Residual solvent control
• Dose uniformity
• Food compatibility
• Storage stability

A coating that is too dense can delay release or create bioavailability differences. A coating that is too thin may fail during chewing or dispersion in food.

Low-moisture granules

Moisture control is important because flavor systems, sweeteners, and polymer coatings can be hygroscopic. Dry granulation or nonaqueous processing may reduce drying burden and improve stability, although both approaches require close control of powder flow and segregation.

Single-dose sachets

Sachets can reduce dosing errors and improve portability. They also support pediatric adherence programs and hospital distribution. Commercial value is higher where caregivers administer medicine outside the home or where a tablet is difficult to swallow.

Which excipient-related commercial opportunities exist for montelukast sodium?

1. Aspartame-free pediatric products

This is one of the clearest low-complexity opportunities. A reformulated 4 mg or 5 mg chewable product can avoid phenylalanine labeling while retaining a familiar dosage form.

The value proposition is strongest when combined with:

• Sugar-free positioning
• Natural or simplified color system
• Improved cherry or berry flavor
• Smaller tablet size
• Aluminum-free or reduced-metal packaging where relevant

2. Sugar-free and low-cariogenic formulations

Mannitol, xylitol, and high-intensity sweetener combinations can support a sugar-free product. A sugar-free claim must be supported by the complete excipient composition and applicable labeling rules. Xylitol may improve sweetness and cooling sensation but can increase cost and affect compression and moisture behavior.

3. Lactose-free tablets

A lactose-free 10 mg tablet can address patients with lactose intolerance and simplify excipient declarations. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a proprietary co-processed excipient can replace lactose.

The most commercially practical approach is usually a conventional immediate-release tablet with improved disintegration and no dairy-derived excipient, rather than an expensive advanced delivery system.

4. Dye-reduced or dye-free products

Colorants assist product identification but can create procurement and patient-preference issues. A white or naturally colored product may appeal to pediatric and institutional buyers. The trade-off is a greater need for packaging controls and physical differentiation to prevent medication errors.

5. Orally disintegrating tablets

An orally disintegrating tablet could address patients who have difficulty swallowing. The product must maintain acceptable taste during rapid oral dispersion, which makes particle coating, ion-exchange masking, or protective matrix technology relevant.

Commercial barriers include:

• Taste exposure
• Tablet friability
• Packaging moisture protection
• Dose uniformity at low strength
• Higher manufacturing cost
• Need to demonstrate appropriate dissolution and bioequivalence

An ODT is more defensible than a conventional tablet if the formulation uses a specific particle-coating or taste-masking architecture. The commercial opportunity is narrower because existing chewable tablets already address pediatric administration.

6. Fixed-dose or co-packaged allergy products

Montelukast is often used in patients with asthma and allergic rhinitis, but FDA-approved combinations and co-packaged products create regulatory and commercial complexity. A co-packaged strategy with an antihistamine or inhaled therapy could improve convenience, but it would require careful medical, labeling, and promotional analysis.

The more feasible route is a pharmacy or payer-oriented co-pack rather than a new fixed-dose combination.

What patent protection covers montelukast sodium oral formulations?

The original montelukast composition and product patents have expired or reached the end of their effective commercial life in the United States. Generic montelukast approvals have been available for years, and the active ingredient is not protected by a current composition-of-matter monopoly.[2]

Patent categories relevant to a new product

Patent category	Current commercial relevance
Montelukast composition patents	Largely expired
Conventional tablet formulation patents	Generally weak or expired
Chewable formulation patents	Potentially relevant if claims cover a specific excipient ratio or process
Taste-masked particles	Potentially strong if composition and performance claims are narrow and enabled
Oral granule manufacturing	Potentially protectable through process and particle claims
Packaging and moisture control	Usually secondary protection
Method-of-use patents	Limited value where labeled indications are already established
Combination products	Potentially relevant, but regulatory and clinical complexity is higher

The strongest new intellectual-property position would likely come from a formulation patent claiming a defined montelukast particle, coating, excipient matrix, or manufacturing process. Broad claims to “montelukast with a sweetener” would face significant obviousness and written-description challenges.

What should a formulation patent claim?

Potential claim elements include:

• A specified montelukast particle-size range
• A defined polymer or lipid coating
• Coating thickness or weight-gain range
• A bitterness threshold measured by a validated sensory method
• Rapid dissolution after gastric exposure
• A narrow excipient ratio
• A low-moisture manufacturing process
• Improved stability under accelerated conditions
• A sachet or container system that maintains potency and flow

Patent strength increases when the formulation provides a measurable technical effect, such as reduced bitterness without delayed dissolution or improved stability without a desiccant.

What is the Orange Book status and generic challenge history for montelukast?

Montelukast products have a long generic history. FDA Orange Book listings identify approved reference products, patent information, and exclusivity where applicable.[2] The original Singulair market was challenged by generic manufacturers before the principal commercial exclusivity period ended, and generic entry occurred in the early 2010s.

Paragraph IV litigation is therefore primarily historical for the original montelukast products. A new formulation with a distinct dosage form or excipient system could generate a new patent dispute if the innovator lists patents and generic applicants certify against them.

A generic applicant may use:

• Paragraph III certification if waiting for patent expiration
• Paragraph IV certification to challenge listed patents
• A suitability or abbreviated pathway where applicable
• A 505(b)(2) route for a materially different formulation, depending on the product design

A formulation patent that is not listed in the Orange Book can still create litigation risk through an infringement action, but it may not create the same statutory stay associated with a listed patent.

When does montelukast lose exclusivity?

Montelukast has already lost primary U.S. market exclusivity. The original product’s commercial protection came from patents, regulatory exclusivity, and pediatric extensions rather than from an enduring biologic-style exclusivity period.[1,2]

Event	Commercial effect
Original FDA approval of Singulair	Established reference product
Pediatric studies and labeling expansion	Added pediatric commercial value
Expiration of primary patent protection	Opened market to ANDA applicants
Generic approvals	Shifted competition to price and supply
Current market	Mature generic segment with formulation niches

Montelukast is a small molecule, so biosimilar risk does not apply. Competition comes from ANDA generics, authorized generic strategies, branded generics, and differentiated oral formulations.

How strong is the patent estate for a new montelukast excipient platform?

A conventional excipient substitution has low patent strength. Replacing lactose with mannitol, or aspartame with sucralose, is unlikely to support broad, durable protection by itself.

Patent strength improves under four conditions:

1. The formulation solves a documented problem, such as severe bitterness or moisture instability.
2. The excipient system produces an unexpected technical result.
3. The claims are tied to measurable composition and performance limits.
4. The process is difficult to reproduce without specialized equipment or controls.

A company should combine formulation patents with trade secrets covering flavor development, coating parameters, particle engineering, and scale-up conditions. Regulatory exclusivity is unlikely to provide meaningful protection for a standard generic reformulation.

What manufacturing and regulatory barriers affect commercial launch?

Manufacturing barriers

The principal manufacturing risks are:

• Montelukast segregation in low-dose pediatric products
• Flavor loss during processing or storage
• Coating nonuniformity
• Lubricant-related dissolution changes
• Granule dust and poor sachet flow
• Moisture uptake
• Blend uniformity at commercial scale
• Cross-contamination controls for potent flavors and colored products

Montelukast sodium products require tight control of assay, impurities, dissolution, content uniformity, and stability. Pediatric products add sensory and handling requirements that are not captured by standard tablet specifications.

FDA pathway

A conventional generic tablet, chewable tablet, or granule may be eligible for an ANDA if it meets applicable sameness, bioequivalence, quality, and labeling requirements. A materially different dosage form, delivery system, or clinical use may require a 505(b)(2) application.[3]

A new excipient is not automatically prohibited, but the sponsor must establish safety, quality, and suitability for the intended route and exposure. Use outside established precedent can increase regulatory review, toxicology requirements, and formulation risk.

How does montelukast compare with competing oral allergy medicines?

Montelukast competes with oral antihistamines such as cetirizine, levocetirizine, loratadine, and fexofenadine, as well as inhaled corticosteroids and intranasal therapies. The excipient opportunity differs by category.

Product category	Main differentiation lever	Montelukast opportunity
Oral antihistamines	Sedation profile, taste, rapid onset	Pediatric taste and excipient simplicity
Inhaled corticosteroids	Device and delivery performance	Oral convenience for selected patients
Montelukast tablets	Price and availability	Low-cost reformulation and supply reliability
Pediatric allergy products	Palatability and dosing	Aspartame-free granules and chewables

Montelukast should not be positioned as a universal substitute for inhaled corticosteroid therapy. Commercial claims must remain consistent with the approved indication and FDA boxed warning.

What generic launch scenarios exist for a differentiated montelukast product?

Low-risk scenario

Launch a conventional 10 mg lactose-free, dye-reduced tablet using standard excipients. This minimizes development cost but provides limited pricing power and weak patent differentiation.

Mid-risk scenario

Launch an aspartame-free 4 mg or 5 mg chewable tablet with improved flavor, sugar-free positioning, and a robust sensory package. This offers the most balanced commercial opportunity.

Higher-value scenario

Launch a taste-masked 4 mg oral granule or ODT with a patented particle-coating platform. The product could command greater differentiation, but development, bioequivalence, stability, and manufacturing costs would rise.

Premium specialty scenario

Develop a caregiver-focused sachet system with low dust, food-dispersion compatibility, and precise dosing. This may be attractive for pediatric specialty pharmacies and international markets but requires channel-specific packaging and reimbursement analysis.

What licensing opportunities exist for montelukast excipient technology?

Licensing opportunities are more likely to involve enabling technology than the montelukast molecule. Potential targets include:

• Taste-masking platform owners
• Pediatric flavor and sensory companies
• Fluid-bed coating manufacturers
• Co-processed excipient suppliers
• Sachet and unit-dose packaging companies
• Contract development and manufacturing organizations

A practical licensing structure would combine an upfront payment, development milestones, and a royalty tied to net sales or volume. The license should define ownership of formulation improvements, scale-up data, analytical methods, and regulatory submissions.

The most valuable asset is a platform that can be reused across pediatric respiratory products. Montelukast can function as an initial product for a broader taste-masking or granule portfolio.

Key Takeaways

• Montelukast sodium oral products are mature generics with limited remaining active-ingredient patent protection.
• Excipient strategy is most valuable in pediatric chewable tablets and oral granules.
• Aspartame-free, sugar-free, lactose-free, and dye-reduced products offer practical differentiation.
• Taste masking must be developed alongside dissolution, stability, and pediatric sensory performance.
• Conventional excipient substitution has weak patent value.
• Stronger protection may arise from coated particles, defined excipient ratios, process claims, and measurable bitterness or stability improvements.
• The most attractive near-term product is an aspartame-free 4 mg or 5 mg pediatric chewable formulation.
• The most defensible higher-value product is a taste-masked oral granule or ODT supported by particle-engineering IP.
• Biosimilar competition is irrelevant because montelukast is a small molecule.
• FDA regulatory strategy depends on whether the product remains an ANDA-equivalent dosage form or becomes a materially different 505(b)(2) product.

FAQs

Can montelukast chewable tablets be reformulated without aspartame?

Yes. Aspartame can be replaced with sucralose, acesulfame potassium, steviol glycosides, polyols, or combinations of these systems, subject to acceptable taste, stability, manufacturing, and labeling performance.

Is mannitol a suitable primary excipient for montelukast pediatric products?

Yes. Mannitol supports bulk, compressibility, sugar-free positioning, and a cooling mouthfeel. Its use must be balanced against tablet hardness, friability, hygroscopicity, and mouthfeel.

Does a montelukast granule product need to be mixed with liquid?

Not necessarily. FDA labeling for montelukast oral granules permits direct administration or mixing with specified soft foods, while imposing restrictions on liquid administration.[1]

Can a new montelukast formulation receive market exclusivity?

A new formulation may receive patent protection if it satisfies patentability requirements. Standard regulatory exclusivity for a conventional reformulation is generally limited, so commercial protection would normally depend on patents, trade secrets, product quality, and market access.

Which montelukast dosage form has the greatest commercial potential?

The 4 mg pediatric chewable tablet has the best balance of market need, development feasibility, and differentiation potential. A taste-masked oral granule may offer greater strategic value but carries higher technical and regulatory risk.

References

1. U.S. Food and Drug Administration. (2024). Singulair (montelukast sodium) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-approval-process-drugs/applications-covered-section-505b2

4. U.S. Food and Drug Administration. (2020). Regulatory classification of pharmaceutical co-crystals. Center for Drug Evaluation and Research.